Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1998 1
1999 1
2001 1
2002 3
2004 1
2005 2
2006 2
2008 3
2009 3
2010 2
2011 6
2012 1
2014 1
2016 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
A highly virulent variant of HIV-1 circulating in the Netherlands.
Wymant C, Bezemer D, Blanquart F, Ferretti L, Gall A, Hall M, Golubchik T, Bakker M, Ong SH, Zhao L, Bonsall D, de Cesare M, MacIntyre-Cockett G, Abeler-Dörner L, Albert J, Bannert N, Fellay J, Grabowski MK, Gunsenheimer-Bartmeyer B, Günthard HF, Kivelä P, Kouyos RD, Laeyendecker O, Meyer L, Porter K, Ristola M, van Sighem A, Berkhout B, Kellam P, Cornelissen M, Reiss P, Fraser C; Netherlands ATHENA HIV Observational Cohort†; BEEHIVE Collaboration†. Wymant C, et al. Science. 2022 Feb 4;375(6580):540-545. doi: 10.1126/science.abk1688. Epub 2022 Feb 3. Science. 2022. PMID: 35113714 Free article.
Drug-resistant genotyping in HIV-1 therapy.
Zöllner B, Feucht HH, Weitner L, Adam A, Laufs R. Zöllner B, et al. Among authors: weitner l. Lancet. 1999 Sep 25;354(9184):1120-1. doi: 10.1016/s0140-6736(05)76910-5. Lancet. 1999. PMID: 10509522 No abstract available.
Late presentation for HIV diagnosis and care in Germany.
Zoufaly A, an der Heiden M, Marcus U, Hoffmann C, Stellbrink H, Voss L, van Lunzen J, Hamouda O; ClinSurv Study Group. Zoufaly A, et al. HIV Med. 2012 Mar;13(3):172-81. doi: 10.1111/j.1468-1293.2011.00958.x. Epub 2011 Nov 7. HIV Med. 2012. PMID: 22093171 Free article.
Maraviroc for previously treated patients with R5 HIV-1 infection.
Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, Nadler J, Clotet B, Karlsson A, Wohlfeiler M, Montana JB, McHale M, Sullivan J, Ridgway C, Felstead S, Dunne MW, van der Ryst E, Mayer H; MOTIVATE Study Teams. Gulick RM, et al. N Engl J Med. 2008 Oct 2;359(14):1429-41. doi: 10.1056/NEJMoa0803152. N Engl J Med. 2008. PMID: 18832244 Free PMC article. Clinical Trial.
Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.
Fätkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, Lampiris H, Hirschel B, Tebas P, Raffi F, Trottier B, Bellos N, Saag M, Cooper DA, Westby M, Tawadrous M, Sullivan JF, Ridgway C, Dunne MW, Felstead S, Mayer H, van der Ryst E; MOTIVATE 1 and MOTIVATE 2 Study Teams. Fätkenheuer G, et al. N Engl J Med. 2008 Oct 2;359(14):1442-55. doi: 10.1056/NEJMoa0803154. N Engl J Med. 2008. PMID: 18832245 Free article.
Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial).
Stellbrink HJ, van Lunzen J, Westby M, O'Sullivan E, Schneider C, Adam A, Weitner L, Kuhlmann B, Hoffmann C, Fenske S, Aries PS, Degen O, Eggers C, Petersen H, Haag F, Horst HA, Dalhoff K, Möcklinghoff C, Cammack N, Tenner-Racz K, Racz P. Stellbrink HJ, et al. Among authors: weitner l. AIDS. 2002 Jul 26;16(11):1479-87. doi: 10.1097/00002030-200207260-00004. AIDS. 2002. PMID: 12131185 Clinical Trial.
Resistance data in the ARTEN trial.
Hoffmann C, Schewe CK, Weitner L, Stellbrink HJ. Hoffmann C, et al. Among authors: weitner l. Antivir Ther. 2011;16(7):1135; author's reply 1135-6. doi: 10.3851/IMP1907. Antivir Ther. 2011. PMID: 22024530 No abstract available.
26 results